Growth • Kazia Therapeutics
KZIA
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
37,4%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
5,2%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
-21,4%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
-15,6%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
-0,9%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!